Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.
Type:
Grant
Filed:
July 9, 2014
Date of Patent:
August 21, 2018
Assignees:
Duke University, The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health
Inventors:
Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.
Type:
Grant
Filed:
May 6, 2014
Date of Patent:
November 15, 2016
Assignees:
Duke University, The United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health
Inventors:
Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles Peagram
Abstract: The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.
Type:
Grant
Filed:
October 18, 2011
Date of Patent:
May 21, 2013
Assignees:
Duke University, The United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health
Inventors:
Chien-Tsun Kuan, Darell D Bigner, Ira H Pastan